Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists - Wikidata - awgldk - TriplyDB

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists

http://www.wikidata.org/entity/Q34612781

about

Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Biosimilars: Still Not Quite Ready for Prime Time.Biosimilar biologic drugs: a new frontier in medical care.US Food and Drug Administration Web Site: A Primer for Pharmacists.What Is Your Institution's Position Going To Be on Biosimilars?How to select a nanosimilar.Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?

P2860

Q36164727-7F43E594-FDF6-4674-B8AB-4DD28896B4E5 Q36972833-F193720C-78B0-4C09-BB65-C01166479956 Q39200937-0F09E123-A465-4D8A-92DF-D666FFC12FAB Q42564251-5007CDC7-2161-450C-8829-01ADC7610F8A Q42583206-D81261A7-6B83-45FD-9F75-30C98141113E Q47762210-6259D8EA-7E51-4996-AE5A-96B542BE8B15 Q52337431-ADCD2F19-4830-4D3F-BA54-24E718E6C2E7

P2860

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists

http://www.wikidata.org/entity/Q34612781

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@ast

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@en

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@nl

type

label

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@ast

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@en

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@nl

prefLabel

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@ast

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@en

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@nl

P1433

Q34612781-88BF7394-15ED-4863-BF21-5BEE0468EA82

P1476

Q34612781-9F13FF32-D435-4221-AC62-5E23A0689B6E

P2093

Q34612781-3D9290EE-2ED9-48DC-B2B1-BB75D0B6E956

Q34612781-43552CDB-9656-4BDD-A76D-C550619ACF5C

Q34612781-8BFEDEA5-6E8B-4E3B-97D8-5AA93FA1D6B9

Q34612781-94C79586-7031-4AD3-BC32-8F07266921CC

P2860

Q34612781-0B9F6139-EF3E-48C9-896A-7970276374AD

Q34612781-19050C36-6762-41AD-9691-FC6850F86FA9

Q34612781-24DF207C-98C9-4E0B-B09C-17135A04A90C

Q34612781-361D0685-7681-4C11-A126-92F4C2F3CFD5

Q34612781-45E71D20-7182-4C9D-BB46-9805EBE75B7E

Q34612781-68040558-2628-400D-A354-6E3C87466D00

Q34612781-6BF1F239-8970-4DEF-82AF-E00EB02F9A16

Q34612781-A692A90C-B3DF-4AAB-8390-A247572C90AD

Q34612781-ADF82C1E-70E0-41FE-B6DC-C3DEF1EDC526

Q34612781-C2541FD2-71DD-488D-89F8-A71895E48BA2

P304

Q34612781-72D87E4F-0198-404F-8641-935263D8EA08

P31

Q34612781-D2998B2D-C794-4472-8FDF-7ED25EECA6A3

P356

Q34612781-EBEF34F9-9782-4F90-A897-293032343BF0

P433

Q34612781-621A59BA-9780-423E-806C-2FC995373C33

P478

Q34612781-BCC8CC68-3933-4376-AB01-7039651C8CB4

P577

Q34612781-3DFBF3E5-7A62-4EEB-B8FD-B5E5416CB364

P5875

Q34612781-9404F717-8EF6-4F33-993B-8938398A00C2

P698

Q34612781-64DF8CB6-21BC-4BF1-9344-0362A44EF810

P932

Q34612781-2C6842E6-7861-485E-A07B-FFB1D710F7D2

P356

P1433

Hospital pharmacy

P1476

Formulary Selection Criteria f ...... r US Health-System Pharmacists

@en

P2093

Ali McBride

http://www.w3.org/2001/XMLSchema#string

James G Stevenson

http://www.w3.org/2001/XMLSchema#string

Larry Green

http://www.w3.org/2001/XMLSchema#string

Niesha Griffith

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative testing and pharmacovigilance of biosimilars.

Quality of original and biosimilar epoetin products

The challenge of biosimilars.

Biosimilars: pharmacovigilance and risk management.

The regulatory framework of biosimilars in the European Union.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Comparability and biosimilarity: considerations for the healthcare provider.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

The market for follow-on biologics: how will it evolve?

National survey on the effect of oncology drug shortages on cancer care.

P304

813-825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ4909-813

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269186855

http://www.w3.org/2001/XMLSchema#string

P698

25477613

http://www.w3.org/2001/XMLSchema#string

P932

4252185

http://www.w3.org/2001/XMLSchema#string